Parker Institute for Cancer Immunotherapy Taps Nonprofit Fundraising Veteran as Chief Advancement Officer — Parker Institute for Cancer Immunotherapy (PICI)

Event summary

Maria Olson appointed Chief Advancement Officer at Parker Institute for Cancer Immunotherapy (PICI) on September 9, 2026.
Olson brings 20+ years of nonprofit fundraising experience, including roles at American Cancer Society and American Heart Association.
At American Cancer Society, Olson grew regional recurring revenue from $44M to $85M over three years, a 25% year-over-year increase.
PICI aims to leverage Olson's expertise to expand philanthropic support for its cancer immunotherapy research network.

The big picture

The appointment of Maria Olson as Chief Advancement Officer comes at a critical juncture for PICI, as it seeks to scale its collaborative model for cancer immunotherapy research. With a portfolio of 17 biotech ventures and over $4B raised in capital, PICI is positioning itself to bridge the gap between scientific discovery and patient access. Olson's track record in fundraising and donor engagement suggests a strategic emphasis on expanding the organization's philanthropic community to support bold ideas and breakthrough research.

What we're watching

Fundraising Momentum: Whether Olson can replicate her past fundraising success at PICI, given the organization's focus on high-risk, high-reward cancer immunotherapy research.
Strategic Partnerships: How Olson's background in strategic partnerships will influence PICI's ability to secure transformational gifts and expand its donor base.
Scientific Translation: The pace at which PICI can advance promising discoveries from the laboratory to patients, supported by Olson's philanthropic efforts.